1 | 5 ASA, enemas, suppositories, corticosteroids | - | - | - | - | [1] 97 97 |
2 | ACEI/ARB and corticosteroids | - | - | - | - | [1] 66 66 |
3 | Azithromycin + N-acetylcystein + inhaled corticosteroid | [1] Azithromycin Azithromycin | [2] D06390
D06390
,
D07486
| - | - | [1] 228 228 |
4 | Chronic Corticosteroid Therapy | - | - | - | - | [1] 113 113 |
5 | Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 85 85 |
6 | Corticosteroid | - | - | - | - | [9] 13 13, 42, 43, 44, 45, 66, 96, 97, 222 |
7 | Corticosteroid (CS) | - | - | - | - | [1] 41 41 |
8 | Corticosteroid and azathioprine | [1] Azathioprine Azathioprine | [1] D00238
D00238
| - | - | [4] 42 42, 43, 44, 45 |
9 | Corticosteroid and non-biological agents. | - | - | - | - | [1] 46 46 |
10 | Corticosteroid or NSAID | - | - | - | - | [1] 46 46 |
11 | Corticosteroid treatment (Methylprednisolone or prednisolone) | [2] Methylprednisolone Methylprednisolone, Prednisolone | [2] D00407
D00407
,
D00472
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 64 64 |
12 | Corticosteroids | - | - | - | - | [12] 41 41, 46, 49, 63, 64, 97, 107, 113, 164, 220, 296, 300 |
13 | Corticosteroids & tanCART19/20 | - | - | - | - | [1] 13 13 |
14 | Corticosteroids (Aprednislon) | - | - | - | - | [1] 63 63 |
15 | Corticosteroids (prednisone or prednisolone) | [2] Prednisolone Prednisolone, Prednisone | [2] D00472
D00472
,
D00473
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 49 49 |
16 | Corticosteroids +immune suppressive +amino salicylic acid | [1] Salicylic acid Salicylic acid | [1] D00097
D00097
| - | - | [1] 97 97 |
17 | Corticosteroids for Systemic Use | - | - | - | - | [1] 41 41 |
18 | Corticosteroids only | - | - | - | - | [1] 97 97 |
19 | Corticosteroids'therapy | - | - | - | - | [1] 35 35 |
20 | CS (corticosteroids) Only | - | - | - | - | [1] 97 97 |
21 | Cumulative corticosteroid exposure | - | - | - | - | [1] 49 49 |
22 | H02 - Corticosteroidi Sistemici | - | - | - | - | [1] 299 299 |
23 | Intra-articular corticosteroid injection | - | - | - | - | [1] 46 46 |
24 | IV Corticosteroid | - | - | - | - | [1] 97 97 |
25 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | [2] Mesalazine Mesalazine, Methylprednisolone | [2] D00377
D00377
,
D00407
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 97 97 |
26 | Oral corticosteroids | - | - | - | - | [5] 13 13, 46, 97, 171, 251 |
27 | Oral corticosteroids (OCS) | - | - | - | - | [1] 162 162 |
28 | Prophylactic Corticosteroid Taper Regimen | - | - | - | - | [1] 251 251 |
29 | Reactive Corticosteroid Taper Regimen | - | - | - | - | [1] 251 251 |
30 | Rituximab, Cyclophosphamide, and Corticosteroids | [2] Cyclophosphamide Cyclophosphamide, Rituximab | [3] D00287
D00287
,
D02994
,
D07760
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 222 222 |
31 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | [1] 162 162 |
32 | Valproid acid plus corticosteroids | - | - | - | - | [1] 26 26 |